Tecmed (Pty) Limited and Others v Nissho Iwai Corporation and Another

Nissho Iwai Corporation issued summons against Tecmed (Pty) Ltd and four sureties for payment of US $3,606,449.45 arising from goods sold and delivered under a distributorship agreement. The main action was instituted in February 2003. In April 2004, Nissho Iwai merged with Nichimen Corporation under Japanese law. The merged entity was renamed Sojitz Corporation. Under the Japanese Commercial Code (articles 101-103), this was an 'absorption merger' whereby Nissho Iwai ceased to exist and all its assets, liabilities, rights and obligations were succeeded to by Sojitz by operation of law. In May 2006, a Rule 15 notice was served by Bowman Gilfillan purporting to substitute Sojitz for Nissho Iwai as plaintiff. The defendants challenged this notice and Bowman Gilfillan's authority, arguing that Rule 15 did not provide for this type of substitution and that the notice was given on behalf of a non-existent entity. This led to four interlocutory applications: (1) defendants' authority application to set aside the Rule 15 notice; (2) a substantive substitution application by the plaintiff; (3) Nissho Iwai's Rule 30 application; and (4) Sojitz's intervention application.

• Whether a Rule 15 notice can effect substitution of a plaintiff following a merger and universal succession under foreign law
• Whether a substantive application is required to substitute a universal successor as plaintiff
• Whether a substitution application brought in the name of a dissolved entity is a nullity
• Whether the substitution of a universal successor activates the provisions of section 15(2) of the Prescription Act 68 of 1969
• The legal effect of universal succession under Japanese law on pending litigation in South African courts

The appeal was dismissed with costs, including the costs occasioned by the employment of two counsel. The order of the court a quo was upheld, namely that Sojitz Corporation be substituted for Nissho Iwai Corporation as the plaintiff, with consequential amendments to pleadings. The defendants' authority application was dismissed and the plaintiff's Rule 30 application was granted.

Where a corporate entity that is a party to pending litigation undergoes universal succession by operation of foreign law (such that all assets, liabilities, rights and obligations pass to a successor entity and the predecessor ceases to exist), the successor steps into the shoes of the predecessor by operation of law and becomes, in effect, the same legal entity for purposes of the litigation. The formal substitution of the successor as a party to the proceedings, whether by Rule 15 notice or substantive application, does not constitute the termination of the original proceedings or the commencement of new proceedings. Consequently, such substitution does not activate section 15(2) of the Prescription Act 68 of 1969. Universal succession by operation of law is distinguishable from cession of rights after litis contestatio. For purposes of substitution applications, the court will interpret the application purposively, having regard to all the papers including supporting affidavits, and will not find the application to be a nullity merely because the notice of motion refers to a dissolved entity where it is clear from the application as a whole that it is brought by the successor entity.

The court made several observations: (1) The purpose of Rule 15 is merely to provide a simplified form of substitution, while the High Court retains inherent common law power to substitute parties on substantive application where Rule 15 does not apply. (2) Where a substantive application for substitution has been brought, any investigation into the effectiveness of a preceding Rule 15 notice is likely to be a futile exercise - if the substantive application succeeds, the substitution materializes regardless; if it fails, it cannot be saved by a Rule 15 notice. (3) The risk of prejudice in substitution applications is usually less where the correct party has been incorrectly named (misnomer) than where a different party is being substituted, but the criterion remains the same: whether substitution will cause prejudice that cannot be remedied by costs or other suitable order. (4) The court expressed agreement with the reasoning in the English cases Eurosteel Ltd v Stinnes AG and Harper Versicherungs AG v Indemnity Marine Assurance Co Ltd regarding universal succession. (5) The court noted that once the substitution application was properly brought, the defendants should not have proceeded with the authority application, and the plaintiff should never have launched the intervention application.

This case establishes important principles regarding universal succession under foreign law and its recognition in South African civil procedure. It clarifies that where a foreign law provides for universal succession (as opposed to cession), the successor steps into the shoes of the predecessor by operation of law and effectively becomes the same entity for litigation purposes. The case is significant for: (1) recognizing and giving effect to universal succession under foreign (Japanese) corporate law; (2) distinguishing between universal succession and cession for purposes of the Prescription Act; (3) confirming that substitution following universal succession does not trigger section 15(2) of the Prescription Act as it does not constitute new proceedings; (4) applying a pragmatic and purposive approach to interpretation of applications brought in the name of dissolved entities following mergers; and (5) extending the principles in Absa Bank Ltd v Van Biljon (regarding statutory universal succession under South African law) to universal succession under foreign law. The case has practical importance for international commercial litigation in South Africa involving corporate mergers and reorganizations governed by foreign law.